Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03170960 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT03170960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03170960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Exelixis
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 5, 2017
Completion date
September 30, 2027
Enrollment
914 (actual)
Sites
124

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, colorectal cancer, differentiated thyroid cancer, endometrial cancer, gastric cancer, gastroesophageal junction adenocarcinoma, head and neck cancer, hepatocellular carcinoma, lower esophageal cancer, non-small cell lung cancer, ovarian cancer, renal cell carcinoma, triple negative breast cancer, urothelial carcinoma